CytomX Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good Wednesday afternoon, everyone. My name is Malcolm Kuno. Welcome to the 41st Annual JPMorgan Healthcare Conference. With me today is my colleague, Dr. Priyanka Grover, and we are both on Anupam Rama's team. I'm fortunate to be able to present our next company, CytomX today, and I'm speaking on behalf of the company is Sean McCarthy, CEO.
Thanks very much. Thank you very much. Good afternoon, everyone. I'd like to thank the JPMorgan team for the opportunity to present. It's a real pleasure to be here. Before we begin, I would like to remind everyone that during this call, I will be making certain forward-looking statements. Important risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. In my presentation today, I would like to give an overview of CytomX's business strategy and pipeline, including our outlook for 2023.
It's been a very exciting few months for the company as
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |